KoreaMed Synapse

Journal List > J Rheum Dis > v.25(3) > 1098122

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Park: Chronic Hepatitis C Virus Infection, Why Not Treat Now?

Editorial

J Rheum Dis 2018;25(3):151-152.

Published online: 31 July 2018

DOI: https://doi.org/10.4078/jrd.2018.25.3.151

Chronic Hepatitis C Virus Infection, Why Not Treat Now?

Kyung-Su Park

Division of Rheumatology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea

Corresponding to: Kyung-Su Park http://orcid.org/0000-0003-0020-003X Division of Rheumatology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, 93 Jungbu-daero, Paldal-gu, Suwon 16247, Korea. E-mail: pkyungsu@catholic.ac.kr

Received 2 May 20189 May 2018 Accepted 10 May 2018

Copyright © 2018 The Korean College of Rheumatology

This is a Open Access article, which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.

REFERENCES

1. Lee HL, Bae SH, Jang B, Hwang S, Yang H, Nam HC, et al. Reactivation of hepatitis C virus and its clinical outcomes in patients treated with systemic chemotherapy or immunosuppressive therapy. Gut Liver. 2017; 11:870–7.

2. Torres HA, Hosry J, Mahale P, Economides MP, Jiang Y, Lok AS. Hepatitis C virus reactivation in patients receiving cancer treatment: A prospective observational study. Hepatology. 2018; 67:36–47.

3. Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol. 2013; 19:7867–73.

4. Kwon HM, Shin K, Moon JY, Lee SS, Chung WT, Lee J, et al. Transaminase changes in Korean rheumatoid arthritis patients with chronic hepatitis C after biologic therapy. J Rheum Dis. 2018; 25:108–15.

5. Pawlotsky JM. Chronic viral and autoimmune hepatitis. Goldman L, Schafer AI, editors. Goldman-Cecil medicine. 25th ed.New York: Elsevier;2016. p. 1000–6.

6. Maylin S, Laouénan C, Martinot-Peignoux M, Panhard X, Lapalus M, Nicolas-Chanoine MH, et al. Role of hepatic HCV-RNA level on the severity of chronic hepatitis C and response to antiviral therapy. J Clin Virol. 2012; 53:43–7.

7. Ooka K, Lim JK. Treatment of hepatitis C in patients undergoing immunosuppressive drug therapy. J Clin Transl Hepatol. 2016; 4:206–27.

8. Economides MP, Mahale P, Kyvernitakis A, Turturro F, Kantarjian H, Naing A, et al. Concomitant use of direct-acting antivirals and chemotherapy in hepatitis C virus-infected patients with cancer. Aliment Pharmacol Ther. 2016; 44:1235–41.

9. Zein NN. Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005; 42:315–22.

TOOLS

Similar articles